TCGA-50-6590-01A-12R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.520
- G2M_CHECKPOINT+0.480
- E2F_TARGETS+0.450
- MYC_TARGETS_V2+0.450
- IL6_JAK_STAT3_SIGNALING+0.440
- INTERFERON_GAMMA_RESPONSE+0.440
- INTERFERON_ALPHA_RESPONSE+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- INFLAMMATORY_RESPONSE+0.370
- MYC_TARGETS_V1+0.340
Top 10 suppressed
- BILE_ACID_METABOLISM-0.360
- CHOLESTEROL_HOMEOSTASIS-0.260
- PEROXISOME-0.250
- FATTY_ACID_METABOLISM-0.220
- KRAS_SIGNALING_DN-0.200
- HEDGEHOG_SIGNALING-0.190
- XENOBIOTIC_METABOLISM-0.170
- ADIPOGENESIS-0.140
- P53_PATHWAY-0.140
- MYOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516056 | — | — | 0.863 |
| 2 | TCGA-56-8201-01A-11R-2247-07 | — | cohortA1 | 0.861 |
| 3 | SRR8943028 | — | — | 0.859 |
| 4 | X55db60cd.e752.41b4.aa3e.f68d676031f7 | — | cohortA1 | 0.856 |
| 5 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.856 |
| 6 | TCGA-55-A493-01A-11R-A24H-07 | — | cohortA1 | 0.854 |
| 7 | s0112234 | — | — | 0.848 |
| 8 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.846 |
| 9 | TCGA-ZF-AA58-01A-12R-A42T-07 | — | — | 0.846 |
| 10 | TCGA-OR-A5JB-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |